Congo vs Mongolia: Share of the population living with HIV receiving antiretroviral therapy
Congo
33.7%
in 2024
Mongolia
40.6%
in 2024
Congo rank
141st
Mongolia rank
139th
Share of the population living with HIV receiving antiretroviral therapy over time
- Congo
- Mongolia
How they compare
Mongolia currently reports 40.6% against 33.7% in Congo, a difference of 6.9%.
That makes Mongolia's figure about 1.2 times Congo's.
The two have swapped places 4 times across 35 shared years of data; in 1990 it was Mongolia ahead.
Congo ranks 141st and Mongolia ranks 139th of 149 countries.
Across the 4 decades both report, Congo averaged higher in 1 and Mongolia in 2.
Head to head by decade
| Decade | Congo | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 3.7% | 0.7% | 2.9% | Congo |
| 2010s | 19.8% | 23.0% | 3.2% | Mongolia |
| 2020s | 28.0% | 38.6% | 10.6% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Congo or Mongolia?
- Mongolia, at 40.6% against 33.7% in Congo as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Congo and Mongolia?
- 6.9%, with Mongolia ahead.
- How many years of comparable data are there for Congo and Mongolia?
- 35 years are reported by both, from 1990 to 2024.
- How do Congo and Mongolia rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Congo ranks 141st and Mongolia ranks 139th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.